Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
Chun Loo Gan(University of Calgary), Daniel Yick Chin Heng(University of Calgary), Anil Kapoor(People’s University), J. Connor Wells(Queen's University), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Ben Tran(The Royal Melbourne Hospital), Toni K. Choueiri(Harvard University), Julia Shapiro(Cabrini Hospital), Rana R. McKay(University of California San Diego), Luís Meza(City of Hope), Frede Donskov(Aarhus University Hospital), Jae‐Lyun Lee(Ulsan College), D. Scott Ernst, Lori Wood(Dalhousie University), Andrew Schmidt(Dana-Farber Cancer Institute), Takeshi Yuasa(Japanese Foundation For Cancer Research), Shaan Dudani(William Osler Health System), Christina M. Canil(University of Ottawa), Thomas Powles(National Health Service), Chris Labaki(Beth Israel Deaconess Medical Center)
Cited by 1
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k